Aetion CEO Carolyn Magill spoke with S&P Global Market Intelligence about the company's ongoing partnership with the FDA, which has taken a turn to focus on the COVID-19 pandemic. She also discusses the need for safety and effectiveness monitoring when patients receive a vaccine and the importance of clear, unbiased data to make healthcare decisions in a crisis.
Read More
Read More